BBLG
NASDAQ · Biotechnology
Bone Biologics Corp
$1.40
+0.04 (+2.56%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 842.6K | 775.9K | 707.6K |
| Net Income | 53.5K | 41.0K | 38.8K |
| EPS | — | — | — |
| Profit Margin | 6.3% | 5.3% | 5.5% |
| Rev Growth | +2.0% | +16.5% | +21.7% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 181.7K | 202.0K | 207.8K |
| Total Equity | 1.11M | 952.9K | 1.08M |
| D/E Ratio | 0.16 | 0.21 | 0.19 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 84.6K | 70.9K | 63.0K |
| Free Cash Flow | 39.3K | 30.9K | 34.5K |